Heartsciences provides business update and reports second quarter fiscal 2023 financial results

Patient enrollment close to completion and continue to target fda de novo resubmission around current fiscal year end patient enrollment close to completion and continue to target fda de novo resubmission around current fiscal year end

HSCS Ratings Summary

HSCS Quant Ranking